UConn Spin-off ImStem Biotechnology to Move Forward with Clinical Trial of Investigational New Drug for Treatment of Multiple Sclerosis
/Just as the United States was recognizing the severity of the coronavirus and state governments were reacting to the impending health crisis, a Farmington-based company with ties to the University of Connecticut that has been pursuing a cure for another elusive disease received milestone news from the U.S. Food and Drug Administration (FDA).
Read More